Previous promising data
A phase IIa study, a prospective open-label, multiple-dose, efficacy and safety study of rhNGF eye drops in a cohort of patients with dry eye disease preceded the current study. The phase IIa study, which was supported by Dompé, was conducted in Austria.
The results were published in the British Journal of Ophthalmology (Sacchetti M, et al. Published Online first: 03 April 2019. doi: 10.1136/bjophthalmol-2018-312470). In this study, the authors reported, “The data of this study indicate that rhNGF eye drops in both doses [20 µg/mL or 4 µg/mL] is safe and effective in improving symptoms and signs of [dry eye disease].”
“Dry eye is a complex disease that often is treated incompletely with currently available therapies. We are excited to explore how NGF uniquely addresses the root causes of ocular surface disease and, most importantly, we are intrigued by the extended therapeutic effect seen in earlier studies,” Dr. Toyos concluded.
Melissa Toyos, MD
E: [email protected]
Dr. Toyos is an investigator in the trial. She has no other financial relationships to report.